Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 19/20 | 0.77 |
| ▸ | ERBB2 known ✓ | P04626 | 18/20 | 0.77 |
| ▸ | ABL1 known ✓ | P00519 | 3/20 | 0.69 |
| ▸ | INSR known ✓ | P06213 | 3/20 | 0.69 |
| ▸ | PDGFRB known ✓ | P09619 | 3/20 | 0.69 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.78 |
| ▸ | CDK2 | P24941 | 3/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.69 |
| ▸ | PLK1 | P53350 | 2/20 | 0.69 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.69 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.69 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142106 | 0.91 | EGFR (0.79) | ABCB11EGFRERBB2ABL1INSR | |
| SCHEMBL29387336 | 0.91 | EGFR (0.79) | ABCB11EGFRERBB2ABL1INSR | |
| SCHEMBL4087313 | 0.90 | EGFR (0.68) | ABCB11EGFRERBB2ABL1INSR | |
| Hydrochloric Acid SCHEMBL2511570 | 0.90 | EGFR (0.78) | ABCB11EGFRERBB2ABL1INSR | |
| SCHEMBL15767655 | 0.89 | ABCB11 (0.89) | ABCB11EGFRERBB2ABL1INSR | |
| Lapatinib SCHEMBL31732815 | 0.88 | ABCB11 (1.00) | ABCB11EGFRERBB2ABL1INSR | |
| Lapatinib SCHEMBL1374543 | 0.88 | ABCB11 (1.00) | ABCB11EGFRERBB2ABL1INSR | |
| Lapatinib SCHEMBL93590 | 0.88 | ABCB11 (1.00) | ABCB11EGFRERBB2ABL1INSR | |
| Lapatinib SCHEMBL29866632 | 0.88 | ABCB11 (1.00) | ABCB11EGFRERBB2ABL1INSR | |
| SCHEMBL15766037 | 0.88 | ABCB11 (0.87) | ABCB11EGFRERBB2ABL1INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871347-B1 | PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2016-08-03 | — | — | EP | disclosed |
| US-20160143909-A1 | PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20150366868-A1 | CANCER TREATMENT METHOD | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-20140335177-A1 | PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| EP-2601178-A2 | SALTS OF LAPATINIB | Hetero Research Foundation (IN) | 2013-06-12 | — | — | EP | disclosed |
| US-20130131090-A1 | SALTS OF LAPATINIB | HETERO RESEARCH FOUNDATION (IN) | 2013-05-23 | — | — | US | disclosed |
| US-8444988-B2 | Cancer treatment method | GLAXOSMITHKLINE LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120058113-A1 | CANCER TREATMENT METHOD | NOVARTIS AG (CH) | 2012-03-08 | — | — | US | disclosed |
| WO-2012017448-A2 | SALTS OF LAPATINIB | HETERO RESEARCH FOUNDATION (IN) | 2012-02-09 | — | — | WO | disclosed |
| US-20110312982-A1 | Cancer Treatment Method | NOVARTIS AG (CH) | 2011-12-22 | — | — | US | disclosed |
| EP-1512413-A2 | Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer | GLAXO GROUP LIMITED (GB) | 2005-03-09 | — | — | EP | disclosed |
| EP-1492568-A1 | CANCER TREATMENT METHOD COMPRISING ADMINISTRATION OF AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR | SmithKline Beecham Corporation (US) | 2005-01-05 | — | — | EP | disclosed |
| EP-1488809-A1 | Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-20040053946-A1 | Cancer treatment method | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| US-20030220354-A1 | Quinazoline ditosylate salt compounds | NOVARTIS AG (CH) | 2003-11-27 | — | — | US | disclosed |
| WO-2003086467-A1 | CANCER TREATMENT METHOD COMPRISING ADMINISTERING AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-1353693-A2 | PHARMACEUTICAL COMBINATION CONTAINING A 4-QUINAZOLINEAMINE AND ANOTHER ANTI-NEOPLASTIC AGENT FOR THE TREATMENT OF CANCER | GLAXO GROUP LIMITED (GB) | 2003-10-22 | — | — | EP | disclosed |
| EP-1294715-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002056912-A2 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER CONTAINING A 4-QUINAZOLINEAMINE AND ANOTHER ANTI-NEOPLASTIC AGENT | GLAXO GROUP LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002002552-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160143909-A1 | PHARMACEUTICAL COMPOSITION | ERBB2, ERBB4, ERBB3 | EGFR 28/4885ERBB2 1/4885ABL1 20/4885 |
| US-20130131090-A1 | SALTS OF LAPATINIB | DYRK1B, DYRK4, ERBB2 | EGFR 8/4885ERBB2 3/4885ABL1 7/4885 |
| US-20120058113-A1 | CANCER TREATMENT METHOD | TP53, HNMT, TOP2B | EGFR 361/4885ERBB2 496/4885ABL1 25/4885 |
| US-20110312982-A1 | Cancer Treatment Method | HNMT, TP53, TUBB4A | EGFR 354/4885ERBB2 395/4885ABL1 28/4885 |
| US-20150366868-A1 | CANCER TREATMENT METHOD | TP53, HNMT, TOP2B | EGFR 361/4885ERBB2 496/4885ABL1 25/4885 |
| US-20140335177-A1 | PHARMACEUTICAL COMPOSITION | ERBB2, ERBB4, ERBB3 | EGFR 28/4885ERBB2 1/4885ABL1 20/4885 |
| US-20040053946-A1 | Cancer treatment method | TP53, HNMT, TOP2B | EGFR 361/4885ERBB2 496/4885ABL1 25/4885 |
| US-20030220354-A1 | Quinazoline ditosylate salt compounds | ERBB4, ABL1, ERBB2 | EGFR 64/4885ERBB2 3/4885ABL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.